Everolimus + Calcineurin inhibitors maintenance
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autosomal Dominant Polycystic Kidney Disease
Conditions
Autosomal Dominant Polycystic Kidney Disease
Trial Timeline
Oct 14, 2014 → Nov 11, 2017
NCT ID
NCT02134899About Everolimus + Calcineurin inhibitors maintenance
Everolimus + Calcineurin inhibitors maintenance is a phase 3 stage product being developed by Novartis for Autosomal Dominant Polycystic Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02134899. Target conditions include Autosomal Dominant Polycystic Kidney Disease.
What happened to similar drugs?
1 of 4 similar drugs in Autosomal Dominant Polycystic Kidney Disease were approved
Approved (1) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02134899 | Phase 3 | Completed |
Competing Products
19 competing products in Autosomal Dominant Polycystic Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-CLS-628 + Placebo | AbbVie | Phase 2 | 42 |
| AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B | AstraZeneca | Phase 1 | 36 |
| Placebo + Everolimus | Novartis | Approved | 43 |
| Octreotide + Placebo | Novartis | Phase 2/3 | 38 |
| Bosutinib + Bosutinib + Placebo | Pfizer | Phase 2 | 35 |
| VX-407 | Vertex Pharmaceuticals | Phase 2 | 42 |
| VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE | Vertex Pharmaceuticals | Phase 1 | 33 |
| VX-407 + Placebo + Midazolam + VX-407 | Vertex Pharmaceuticals | Phase 1 | 29 |
| VX-407 + Placebo | Vertex Pharmaceuticals | Phase 1 | 33 |
| Tesevatinib | Sanofi | Phase 1/2 | 32 |
| Tesevatinib + Placebo | Sanofi | Phase 2 | 35 |
| Venglustat + Placebo | Sanofi | Phase 2/3 | 30 |
| Bardoxolone methyl oral capsule + Placebo oral capsule | Biogen | Phase 3 | 29 |
| Lanreotide + saline | Ipsen | Phase 3 | 37 |
| KB105 | Krystal Biotech | Phase 2 | 28 |
| KB105 | Krystal Biotech | Phase 1/2 | 25 |
| Lixivaptan + Placebo | Centessa Pharmaceuticals | Phase 3 | 29 |
| GLPG2737 + Placebo | Galapagos | Phase 2 | 21 |
| QR-1123 | ProQR | Phase 1/2 | 26 |